Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • pharma-news
    • Zydus, China Medical...

    Zydus, China Medical System enter licensing agreement for desidustat

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2020-01-21T15:15:37+05:30  |  Updated On 21 Jan 2020 3:15 PM IST
    Zydus, China Medical System enter licensing agreement for desidustat

    Under the license agreement, CMS will pay Zydus an initial upfront payment, regulatory milestones, sales milestones and royalties on net sales of the product. The commercial terms of the license agreement are confidential. CMS will be responsible for the development, registration and commercialization of Desidustat in Greater China.

    Ahmedabad: Zydus, a discovery-based global pharmaceutical company today announced that it has entered into a licensing agreement with China Medical System Holdings Limited (CMS) for the development and commercialization of Desidustat, a novel oral HIF-PH inhibitor for the treatment of anaemia in patients with Chronic Kidney Disease (CKD) not-on-dialysis and for the treatment of Anemia CKD patients on dialysis in Greater China (Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region and Taiwan).

    It has been reported that more than 120 million people are estimated to be living with CKD in China1 (Source: Zhang L, Wang F, Wang L et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet 2012; 379: 815–822). CKD is a serious medical condition which is an unmet healthcare need involving gradual loss of functioning of kidneys eventually leading to kidney failure. If kidneys are healthy they will naturally secrete beneficial levels of a hormone called erythropoietin (EPO), which encourages red blood cell production that carries oxygen to the muscles and brain. If the kidneys are impaired they will produce reduced levels or tire of EPO production completely, leading to fatigue and anaemia.

    Anaemia is one of the frequent complications of CKD. A survey in China showed that the prevalence of anaemia in patients at CKD stage 1 to 5 was 22.0%, 37.0%, 45.4%, 85.1%, and 98.2%, respectively2. The target-achieving rate was only 8.2% for anaemia patients in nondialysis CKD and 35.2% for dialysis CKD, showing unmet healthcare need3.

    Speaking on the development, Pankaj R. Patel, Chairman, Zydus Group said, "The licensing agreement with CMS will facilitate the development and commercialization of Desidustat in Greater China, and make this innovative candidate available to millions of CKD patients living with anaemia."

    Under the license agreement, CMS will pay Zydus an initial upfront payment, regulatory milestones, sales milestones and royalties on net sales of the product. The commercial terms of the license agreement are confidential. CMS will be responsible for the development, registration and commercialization of Desidustat in Greater China.

    Read also: Zydus Cadila unveils affordable anti-diabetic drug Vildagliptin under brands Vinglyn, Vinglyn M

    Zydus had initiated two Phase III trials of Desidustat. The DREAM-ND (ClinicalTrials.gov Identifier: NCT04012957) Phase III trial is being conducted in CKD patients not-on-dialysis. The DREAM-D Phase III trial (ClinicalTrials.gov Identifier: NCT04215120) is being conducted in CKD patients on Dialysis. Desidustat had previously met its primary endpoints in Phase II clinical studies and showed a good safety profile. The Phase I trials were earlier completed in Australia.

    Read also: Zydus Cadila to divest two major units- Vivo, Gynova for Rs 1200 crore: Report

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok